Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America

This issue of Hematology/Oncology Clinics is edited by Dr. Jennifer Brown and focuses on Chronic Lymphocytic Leukemia. Article topics include: What Have Recent Genomic Advances Taught us About CLL?, Biology of CLL in Different Microenvironments,What is the Significance of Stereotyped BCRs in CLL?, Understanding Immunodeficiency in CLL, MBL vs CLL: How Important is the Distinction?, Risk Stratification of CLL in 2012, Minimal Residual Disease Measurement in CLL, The BTK Inhibitor PCI-32765 in CLL, and Evolving Role of Stem Cell Transplantation in CLL.

This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown︎, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue will include: Chronic Lymphocytic Leukemia: Do We Know the Cell of Origin Yet?; Significance of BCR Stereotypy; Prognostic and Predictive Implications of Cytogenetics and Genomics; Role of Epigenetics in Chronic Lymphocytic Leukemia; Genomics of Resistance to Targeted Therapies; First Line Therapy for Chronic Lymphocytic Leukemia; The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia Therapy; BTK Inhibitors; Minimal Residual Disease; Should Undetectable MRD Be the Goal of Chronic Lymphocytic Leukemia Therapy?; Management of Chronic Lymphocytic Leukemia after Progression on BTK Inhibitors; Role of PI3K Inhibitors in Chronic Lymphocytic Leukemia; Can We Restore the Immunodeficiency of Chronic Lymphocytic Leukemia?; and Immune Therapy for Chronic Lymphocytic Leukemia

This issue of Hematology/Oncology Clinics of North America, guest edited by Drs. Bipin Savani and Mohamad Mohty, is devoted to Bone Marrow Transplantation. Articles in this issue include: Acute Myeloid Leukemia (AML); Acute Lymphoid Leukemia (ALL); Myelodysplastic Syndrome (AML); Myeloproliferative disorders (MPD); Chronic Lymphoid Leukemia; Chronic Myeloid Leukemia (CML); Multiple Myeloma and Amyloidosis; Non-Hodgkin Lymphoma (NHL); Hodgkin Lymphoma (HL); Severe Aplastic Anemia (SAA) and Paroxysmal Nocturnal Hemoglobinuria (PNH); Sickle Cell Anemia; Thalassemia; Benign immunodeficiency diseases; and Referral to transplant centers.

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton's Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions.

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. Guru P. Sonpavde, is devoted to Bladder Cancer. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Epidemiology of bladder cancer, The molecular biology of bladder cancer and potential implications for therapy, Current therapy for metastatic urothelial carcinoma, Current perioperative therapy for muscle invasive urothelial carcinoma, Current therapy and emerging intravesical agents to treat non-muscle invasive bladder cancer, Diagnosis and staging of bladder and upper tract urothelial cancer, Surgery for bladder and upper tract urothelial cancer, Bladder conserving therapy for muscle invasive bladder cancer: opportunities to incorporate molecular profiling, Emerging immunotherapy for bladder cancer, Emerging targeted therapy for bladder cancer, Real world outcomes of patients with bladder cancer, Preclinical systems to develop bladder cancer therapeutics, Developing precision medicine for bladder cancer, and Future Directions in Bladder Cancer Treatment and Research.

This issue of Hematology/Oncology Clinics is guest edited by Dr. Christoph Klein and focuses on the topic of Neutropenia. Article titles include: Homeostasis and migration of neutrophil granulocytes,Granulocyte-colony Stimulating Factor (G-CSF) receptor signaling,New Granulocyte-colony Stimulating Factor (G-CSF) Receptor Signaling Pathways ,Neutrophil elastase (ELANE) – Genetics and Pathophysiology,Autosomal recessive variants of Severe congenital neutropenia (SCN),Leukocyte Adhesion Deficiency (LAD), and Genotype-phenotype correlations in Severe congenital neutropenia (SCN).